Tag-1 and tag-2 proteins and uses thereof
AssigneeUniversity of Virginia Patent Foundation
InventorsKevin Hogan, Craig Slingluff
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a newly discovered gene family with multiple isoforms, designated TAG-1, TAG-2a, TAG-2b, TAG-2c, and TAG-3, nucleic acid sequences encoding those proteins, and antibodies generated against said proteins. The genes, proteins, and peptides described herein may be used as diagnostic indicators of the presence of cancer and/or used in therapeutics to treat cancer.
Claims30
A purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 22, SEQ ID NO:
- 23 and SEQ ID NO:
- 24.
An isolated, purified or synthetic peptide of about 9 to about 15 residues in length that comprises an amino acid sequence identical to a contiguous 9 amino acid sequence of SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 22, SEQ ID NO:
- 23 and SEQ ID NO:
- 24, with the proviso that the sequence is not SEQ ID NO:
- 12.
An antigenic composition comprising a purified amino acid sequence selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and bioactive fragments of such sequences;
- and
- a pharmaceutiacally acceptable carrier.
An isolated, purified or synthetic peptide of about 9 to about 15 residues in length that comprises an amino acid sequence identical to SEQ ID NO:
- 12.
An antibody that specifically binds to a polypeptide selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 22, SEQ ID NO:
- 23 and SEQ ID NO:
- 24.
An antibody that specifically binds to the amino acid sequence of SEQ ID NO:
- 12.
A nucleic acid sequence comprising a sequence selected from the group consisiting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4 and SEQ ID NO:
- 5.
A recombinant gene construct, said construct comprising a non-native promoter operably linked to a nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4 and SEQ ID NO:
- 5.
A process for inducing a cytotoxic T lymphocyte (CTL) in vitro that is specific for a melanoma cancer cell, said method comprising contacting a precursor CTL with an immunogen comprising the sequence of SEQ ID NO:
- 12 under conditions that generate a CTL response to the melanoma cancer cell.
A melanoma-specific immunogen comprising a melanoma-specific CTL epitope, wherein at least one of said epitopes is identical to a sequence selected from the group consisting of SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21.
A method of detecting cancer, said method comprising the step of
- screening a biological sample obtained from a patient for elevated levels or inappropriate expression of TAG polypeptides.
A recombinant host cell comprising an exogenous nucleic acid sequence that encodes for a polypeptide comprising an amino acid sequence selected from the group consisiting of SEQ ID NO:
- 6-11 and 22-24.
Dependencies are inferred from the claim text.